INSERM Unité 970, Paris Cardiovascular Research Center - PARCC, Paris, France.
Gastroenterology. 2012 Jul;143(1):166-76.e6. doi: 10.1053/j.gastro.2012.03.040. Epub 2012 Mar 30.
BACKGROUND & AIMS: Circulating membrane-shed microparticles (MPs) participate in regulation of vascular tone. We investigated the cellular origins of MPs in plasma from patients with cirrhosis and assessed the contribution of MPs to arterial vasodilation, a mechanism that contributes to portal hypertension.
We analyzed MPs from blood samples of 91 patients with cirrhosis and 30 healthy individuals (controls) using flow cytometry; their effects on the vascular response to vasoconstrictors were examined in vitro and in vivo.
Circulating levels of leuko-endothelial (CD31(+)/41(-)), pan-leukocyte (CD11a(+)), lymphocyte (CD4(+)), and erythrocyte (CD235a(+)) MPs were higher in patients with cirrhosis than in controls. Plasma of patients with cirrhosis contained hepatocyte-derived MPs (cytokeratin-18(+)), whereas plasma from controls did not. The severity of cirrhosis and systemic inflammation were major determinants of the levels of leuko-endothelial and hepatocyte MPs. MPs from patients with advanced cirrhosis significantly impaired contraction of vessels in response to phenylephrine, whereas MPs from healthy controls or from patients of Child-Pugh class A did not. This effect depended on cyclooxygenase type 1 and required phosphatidylserine on the surface of MPs. Intravenous injection of MPs from patients with cirrhosis into BALB/C mice decreased mean arterial blood pressure.
Cirrhosis is associated with increases in circulating subpopulations of MPs, likely resulting from systemic inflammation and liver cell damage. The overall pool of circulating MPs from patients with advanced cirrhosis impairs vasoconstrictor responses and decreases blood pressure, contributing to the arterial vasodilation associated with portal hypertension.
循环膜脱落的微颗粒(MPs)参与血管张力的调节。我们研究了肝硬化患者血浆中 MPs 的细胞来源,并评估了 MPs 对动脉舒张的贡献,这是导致门脉高压的一种机制。
我们使用流式细胞术分析了 91 例肝硬化患者和 30 例健康个体(对照组)的血液样本中的 MPs;在体外和体内研究了它们对血管对血管收缩剂反应的影响。
肝硬化患者的循环白细胞-内皮(CD31(+)/41(-))、全白细胞(CD11a(+)、淋巴细胞(CD4(+)和红细胞(CD235a(+))MPs 水平高于对照组。肝硬化患者的血浆中含有肝细胞来源的 MPs(细胞角蛋白-18(+)),而对照组的血浆中则没有。肝硬化的严重程度和全身炎症是白细胞-内皮和肝细胞 MPs 水平的主要决定因素。来自晚期肝硬化患者的 MPs 显著抑制了对苯肾上腺素的血管收缩反应,而来自健康对照组或 Child-Pugh 分级 A 患者的 MPs 则没有。这种作用依赖于环氧化酶 1,并且需要 MPs 表面的磷脂酰丝氨酸。将来自肝硬化患者的 MPs 静脉注射到 BALB/C 小鼠体内,可降低平均动脉血压。
肝硬化与循环中 MPs 的亚群增加有关,这可能是由全身炎症和肝损伤引起的。来自晚期肝硬化患者的循环 MPs 总体池抑制血管收缩反应并降低血压,导致与门脉高压相关的动脉舒张。